Comparison
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 vs 17q24 2 Microdeletion Syndrome C5680185
Clinical comparison between 3 Methylcrotonyl Coa Carboxylase 2 Deficiency and 17q24 2 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
A rare metabolic disorder affecting leucine breakdown. Infants may show developmental delay, seizures, and metabolic crises. Treatment involves biotin supplements and dietary protein restriction.
17q24 2 Microdeletion Syndrome C5680185
A rare genetic disorder caused by deletion of genetic material on chromosome 17. Individuals may have developmental delays, facial features, and other medical issues. Care is supportive and multidisciplinary.
6 comparison axes
Onset
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
0-null
17q24 2 Microdeletion Syndrome C5680185
0-null
Onset patterns differ
Severity
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
severe
17q24 2 Microdeletion Syndrome C5680185
moderate
Different severity levels
Chronic
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
Chronic
17q24 2 Microdeletion Syndrome C5680185
Chronic
Differing course
Communicable
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
No
17q24 2 Microdeletion Syndrome C5680185
No
Different transmission
Body System
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
metabolic
17q24 2 Microdeletion Syndrome C5680185
congenital
Same/different system
Category
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
metabolic
17q24 2 Microdeletion Syndrome C5680185
genetic
Different category
Bottom line
3-methylcrotonyl-coa-carboxylase-2-deficiency-C1859499 and 17q24-2-microdeletion-syndrome-C5680185 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 | 17q24 2 Microdeletion Syndrome C5680185 | Discriminating power |
|---|---|---|---|
| Acute metabolic crisis | May involve leucine-related decompensation, sometimes with seizures. | Not described as a primary metabolic-crisis disorder. | High |
| Developmental delay | May occur alongside metabolic or neurologic features. | May occur with congenital or facial features. | Moderate |
| Facial or congenital features | Not established as a defining feature. | Facial features and other medical issues may occur. | Moderate |
When to favor each condition
Choose 3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 when
Suspected leucine-pathway metabolic disorder
The source describes impaired leucine breakdown and possible crises.
Moderate
Abnormal metabolic screening result
Biochemical findings can suggest MCC deficiency but need confirmation.
High
Recurrent decompensation with seizures
This pattern fits the described metabolic phenotype better.
Moderate
Choose 17q24 2 Microdeletion Syndrome C5680185 when
Delay with congenital or facial features
The source describes a chromosomal deletion phenotype.
Moderate
Microarray shows a 17q24.2 deletion
A deletion supports this condition when clinically correlated.
High
Supportive congenital care without crises
Care is described as multidisciplinary rather than diet-based.
Moderate
How key tests differ
| Test | 3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499 | 17q24 2 Microdeletion Syndrome C5680185 | Interpretation |
|---|---|---|---|
| Organic acids and acylcarnitines | May show leucine-pathway metabolites; cutoffs not given. | Not expected to establish the syndrome. | An abnormal metabolite result is not itself a confirmed diagnosis. |
| MCCC2-related genetic testing | Pathogenic variants may confirm the enzyme disorder. | Not the primary diagnostic test. | Gene results help separate enzyme deficiency from deletion. |
| Chromosomal microarray | A 17q24.2 deletion is not expected. | May identify the microdeletion. | Deletion findings require clinician interpretation and correlation. |
Prognosis comparison
3 Methylcrotonyl Coa Carboxylase 2 Deficiency C1859499
- Outcome
- Chronic metabolic condition; individual outcome is not established and may vary with crises and neurologic involvement.
- Factors
- Crisis prevention, nutrition, clinician-directed biotin, and seizure management; no dose is specified.
17q24 2 Microdeletion Syndrome C5680185
- Outcome
- Chronic congenital condition with variable developmental and medical needs; mortality is not established.
- Factors
- Associated anomalies, developmental support, and access to multidisciplinary care.
Time frame: Both are lifelong; early childhood may be especially active, but course is individual.
Severity labels differ, but they do not predict one person's outcome.
Complications comparison
| Complication | Presentation |
|---|---|
| Metabolic decompensation | Acute crises are possible. Not characteristic in the supplied description. Vomiting, lethargy, poor feeding, or seizures need urgent assessment. |
| Seizures | Reported as a possible feature. Not specifically established here. Neurologic problems may occur, but causes differ. |
| Associated medical complexity | Mainly metabolic and neurologic concerns. Other congenital or medical issues may occur. Their extent is variable and not quantified. |
Patient education highlights
- HighNot contagious
Neither condition is an infection or transmitted between people.
- HighUrgent warning signs
Poor feeding, vomiting, lethargy, or seizures require prompt clinical assessment.
- MediumConfirm the diagnosis
An abnormal test is not automatically a diagnosis; specialists should interpret results.